SF-5302 would add a new section to Minnesota Statutes, chapter 62Q; it does not amend a specific existing section in the supplied text. Its stated goal is to set rules for drugs covered by the federal Medicare Drug Price Negotiation Program. The bill was introduced and referred to the Senate Health and Human Services Committee; it is not law. If enacted, it would take effect January 1, 2027.
No cost estimate is provided in the available material.
Bills on related subjects, starting with Minnesota.
A bill would cap prices for Medicare-negotiated drugs in Minnesota and require reimbursements at the higher of the cap or NADAC, with withdrawal penalties; effective January 1, 2027.
Status
Authors added Berg; Kozlowski; Pursell; Jordan; Kraft; Johnson, P.; Freiberg; Virnig; Liebling; Gottfried; Youakim; Greenman; Feist; and Falconer
Lawmakers would require a Minnesota tax add-back for direct-to-consumer pharmaceutical marketing expenses, starting with the 2027 tax year.
Status
Referred to Taxes
Lawmakers would require addbacks of qualifying direct-to-consumer pharma marketing deductions for Minnesota income and corporate taxes starting in 2027.
Status
Introduction and first reading, referred to Taxes
Minnesota lawmakers file a bill to cap credit-card interest at 10% once federal changes take effect. The cap would apply to banks and credit unions.
Status
Introduction and first reading, referred to Commerce Finance and Policy